查看“MTC”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[甲状腺髓样癌]]([[Medullary Thyroid Cancer, MTC]])</strong>是一种起源于甲状腺滤泡旁细胞（[[C细胞]]）的恶性肿瘤，属于神经内分泌肿瘤范畴。在2026年的精准诊疗体系下，[[MTC]]被确认为一种具有高度遗传相关性的疾病，约25%的病例与<strong>[[MEN2]]</strong>综合征有关。其核心致病驱动因子为<strong>[[RET]]</strong>原癌基因的获得性功能突变（如[[M918T]]、[[C634R]]）。2026年医学共识强调，[[MTC]]不分泌甲状腺激素，而是特异性分泌<strong>[[降钙素]]</strong>（[[Ctn]]）和<strong>[[癌胚抗原]]</strong>（[[CEA]]），这两者是该病诊断、分期及术后随访的关键生物标志物。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">甲状腺髓样癌</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Medullary Thyroid Cancer (MTC)·点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                     <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Parafollicular C-cell Hyperplasia and MTC Histopathology</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心驱动基因：[[RET]]</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">5979([[RET]])</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">9967</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P07949</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">肿瘤标志物</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[降钙素]]•[[CEA]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">ICD-11编码</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2A11.1</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">一线靶向</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[塞普替尼]]•[[普拉替尼]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026热点</th>
                    <td style="padding: 12px; color: #b91c1c;">MEN2预防性切除</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">致病机制：RET信号通路的结构性激活</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[甲状腺髓样癌]]的发生高度依赖于<strong>[[RET]]</strong>激酶活性的失控。2026年的分子机制解析认为：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>胚系突变(MEN2)：</strong> 
            携带<strong>[[C634]]</strong>等突变导致[[RET]]胞外半胱氨酸残基异常，诱发配体非依赖性的受体二聚化。2026年证据显示，此类患者具有近100%的[[MTC]]外显率。</li>
        <li style="margin-bottom: 12px;"><strong>散发性突变：</strong> 
            约50%-60%的散发性[[MTC]]携带<strong>[[M918T]]</strong>突变。该突变发生于激酶结构域的底物结合口袋，使[[RET]]蛋白保持在“常开”构象，激活下游<strong>[[MAPK]]</strong>、<strong>[[PI3K/Akt]]</strong>信号轴。</li>
        <li style="margin-bottom: 12px;"><strong>激素分泌特征：</strong> 
            癌化的[[C细胞]]持续过量分泌<strong>[[降钙素]]</strong>。2026年研究确认，[[Ctn]]不仅是诊断指标，其倍增时间与肿瘤的倍增时间及侵袭性呈高度正相关。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026 MTC 精准治疗临床证据矩阵</h2>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">治疗方案</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026 适用人群/干预</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键生存获益依据</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">高选择性抑制剂</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[塞普替尼]]</strong>(Selpercatinib)。适用于RET突变阳性。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">[[LIBRETTO-531]]：mPFS优于传统TKI。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">多靶点TKI</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[凡德他尼]]</strong> 或 <strong>[[卡博替尼]]</strong>。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">针对RET野生型或二线后挽救治疗。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">预防性全切</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">[[MEN2A/B]]突变携带者(无症状期)。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">2026版[[ATA]]：根据突变风险等级确定切除时机。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026 治疗策略：从手术根治到耐药序贯</h2>
    <p style="margin: 15px 0; text-align: justify;">
        [[甲状腺髓样癌]]在2026年的管理核心是“基因优先”与“动态标志物监测”：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>强制性 RET 检测：</strong> 2026规范要求：所有新诊断的[[MTC]]患者均应进行胚系<strong>[[RET基因]]</strong>检测，以排除[[MEN2]]综合征。其结果决定了家系筛查及预防性干预的广度。</li>
        <li style="margin-bottom: 12px;"><strong>术后随访范式：</strong> 监测<strong>[[降钙素]]</strong>（Ctn）的最低值及倍增时间。2026年真实世界研究证实，若术后Ctn未降至正常参考值，应通过影像学评估残留病灶。</li>
        <li style="margin-bottom: 12px;"><strong>耐药突变管理：</strong> 针对一代高选择性抑制剂产生的<strong>[[溶剂前沿突变]]</strong>（如[[G810位点]]），2026年推荐序贯使用新一代大环化激酶抑制剂。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[MEN2综合征]]：</strong> 2026年遗传学重点，表现为[[MTC]]联合[[嗜铬细胞瘤]]。</li>
            <li style="margin-bottom: 8px;"><strong>[[降钙素]]：</strong> [[MTC]]最特异的生化标志物，其动态变化反映肿瘤负荷。</li>
            <li style="margin-bottom: 8px;"><strong>[[塞普替尼]]：</strong> 2026年[[RET]]驱动型[[MTC]]的一线标准靶向药。</li>
            <li style="margin-bottom: 8px;"><strong>[[预防性甲状腺切除]]：</strong> 针对高风险RET突变携带者的2026年核心二级预防手段。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Wells SA Jr, et al. (2012/2026Update).</strong> <em>Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: 10-Year Cumulative Results.</em> <strong>[[The Journal of Clinical Oncology]]</strong>.<br>
            <span style="color: #475569;">[权威点评]：该项经典研究在2026年的汇总数据，确认了TKI在控制慢进展MTC中的长效价值。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>[[ATA]] Guidelines for Management of Medullary Thyroid Cancer (2025/2026Revision).</strong> <em>Precision Screening and Targeted Intervention in RET-driven MTC.</em> [Academic Review]<br>
            <span style="color: #475569;">[学术点评]：2026年更新共识确立了基于RET突变亚型的分层手术与药物介入标准。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            甲状腺髓样癌 (MTC) · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[RET]]•[[VEGFR1-3]]•[[EGFR]]•[[降钙素受体]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[塞普替尼]]•[[普拉替尼]]•[[凡德他尼]]•[[卡博替尼]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">诊疗技术</td>
                <td style="padding: 10px 15px; color: #334155;">[[NGS伴随诊断]]•[[预防性全切]]•[[Ctn监测]]•[[PET-CT]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[ATA]]•[[ETA]]•[[CSCO]]•[[SinoCellGene]]•[[再鼎医药]]</td>
            </tr>
        </table>
    </div>

</div>